|
|
|
|
|
|
|
|
|
|
Ovarian Cancer: Future of PARP Inhibitor Olaparib Still Uncertain in platinum-sensitive disease
"....Median overall survival reported here at the Society of
Gynecologic Oncology's Annual Meeting on Women's Cancer was 29.7 months
for olaparib and 29.9 for placebo.
Because of this, the drug's manufacturer is not moving forward with a Phase III trial in this disease...."
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.